Pharmacyclics LLC et al v. Alvogen Pine Brook LLC et al

  1. April 30, 2024

    Pharmacyclics Can't Score Fees After Imbruvica Patent Win

    Delaware's top federal judge on Tuesday told AbbVie's Pharmacyclics LLC unit that it was "also guilty of vexatious conduct" and had no standing to seek legal fees after it won a patent infringement suit against generic-drug rivals over its branded blockbuster cancer drug Imbruvica.

  2. February 22, 2023

    AbbVie, J&J Units Say Del. Judge's Rebukes Bolster Fee Bid

    Pharmacyclics LLC and Janssen Biotech Inc. are urging a Delaware federal judge to grant them fees after their win in patent infringement litigation over the cancer drug Imbruvica, noting the judge himself repeatedly lost patience with the losing companies.

  3. October 07, 2022

    Alvogen Continues IP Fight Over Cancer Drug Imbruvica

    In a rematch over the leukemia medication Imbruvica, AbbVie's Pharmacyclics LLC and Johnson & Johnson's Janssen Biotech urged the Federal Circuit Friday to uphold a lower court ruling that their four patents related to the blockbuster drug are valid.

  4. August 19, 2021

    AbbVie, Janssen Win IP Fight Over Cancer Drug Imbruvica

    A Delaware federal judge on Thursday ruled in favor of AbbVie and Janssen Biotech Inc. in their 2019 suit against Alvogen over its planned generic version of the blockbuster cancer drug Imbruvica, holding that all four patents in the case were not shown to be invalid.